GLPG3970 (compound 32) is a dual inhibitor of SIK2 and SIK3, with IC50 of 282.8 nM, 7.8 nM and 3.8 nM for SIK1, SIK2 and SIK3, respectively. It has the potential to treat autoimmune and inflammatory diseases.

GLPG3970 (compound 32) is a dual inhibitor of SIK2 and SIK3, with IC50 of 282.8 nM, 7.8 nM and 3.8 nM for SIK1, SIK2 and SIK3, respectively. It has the potential to treat autoimmune and inflammatory diseases.

GLPG3970 (compound 32) is a dual inhibitor of SIK2 and SIK3, with IC50 of 282.8 nM, 7.8 nM and 3.8 nM for SIK1, SIK2 and SIK3, respectively. It has the potential to treat autoimmune and inflammatory diseases.

Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt (Salinomycin sodium) acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt (Salinomycin sodium) shows selective activity against human cancer stem cells.

AZD-5462(Example 1) is a modulator of RXFP1, the cognate receptor for human relaxin, that belongs to the GPCR family 1c number. AZD-5462 exhibits anti-fibrotic and anti-inflammatory properties.

AZD-5462(Example 1) is a modulator of RXFP1, the cognate receptor for human relaxin, that belongs to the GPCR family 1c number. AZD-5462 exhibits anti-fibrotic and anti-inflammatory properties.

AZD-5462(Example 1) is a modulator of RXFP1, the cognate receptor for human relaxin, that belongs to the GPCR family 1c number. AZD-5462 exhibits anti-fibrotic and anti-inflammatory properties.

AZD-5462(Example 1) is a modulator of RXFP1, the cognate receptor for human relaxin, that belongs to the GPCR family 1c number. AZD-5462 exhibits anti-fibrotic and anti-inflammatory properties.

DBr-1 is a DCAF1-BRD9 PROTAC, created by linking the BRD9 binder BI-956448 to the DCAF1 scaffold via a piperidine-aliphatic carbon linker. It is a potent and selective degrader of BRD9 with a DC50 of 90 nM. It overcomes intrinsic resistance to VHL-degraders, positioning DCAF1-PROTACs as a promising strategy to counter ligase-mediated resistance.

DBr-1 is a DCAF1-BRD9 PROTAC, created by linking the BRD9 binder BI-956448 to the DCAF1 scaffold via a piperidine-aliphatic carbon linker. It is a potent and selective degrader of BRD9 with a DC50 of 90 nM. It overcomes intrinsic resistance to VHL-degraders, positioning DCAF1-PROTACs as a promising strategy to counter ligase-mediated resistance.